Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on August 31, 2020, with the earliest event reported on that date. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices located in San Francisco, California. The filing primarily addresses a material definitive agreement regarding office space and significant regulatory notices concerning its listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial figures disclosed include:
- Sublease Rent: $14,911.83 per month (including operating expenses and taxes) for approximately 5,263 square feet of office space.
- Stockholders' Equity Threshold: The Company previously failed to maintain the minimum $2,500,000 required by Nasdaq Listing Rule 5550(b)(1).
- Bid Price Requirement: The Company failed to maintain the minimum $1.00 bid price required by Nasdaq Listing Rule 5550(a)(2).
Material Changes and Events
Office Relocation: On August 31, 2020, the Company received landlord consent to sublease office space at 200 Pine Street, Suite 400, San Francisco. The term runs from August 31, 2020, to May 31, 2021. The Company is transitioning operations from its previous location at 201 Mission Street to this new principal administrative headquarters.
Nasdaq Delisting Notice (Bid Price): On September 11, 2020, the Company received notice from Nasdaq regarding continued non-compliance with the $1.00 minimum bid price requirement. Despite having previously obtained an 180-day compliance period, Nasdaq determined to delist the securities unless the Company requests a hearing.
Nasdaq Compliance Update (Stockholders' Equity): The Company previously received notice on August 17, 2020, regarding non-compliance with the $2,500,000 stockholders' equity requirement. However, on September 9, 2020, Nasdaq determined the Company was in compliance with this specific rule based on a prior filing, though future non-compliance could trigger delisting.
Outlook, Risks, and Management Commentary
Management Action Plan: The Company intends to timely request a hearing before the Nasdaq Hearings Panel to seek an extension to evidence compliance with the minimum bid price rule. This request is expected to stay any suspension or delisting action pending the hearing's outcome.
Risks and Contingencies: There is no assurance that the Nasdaq Hearings Panel will grant the request for continued listing or that the Company will achieve compliance within any granted extension period. Failure to maintain compliance with Nasdaq Listing Rule 5550(b)(1) upon the next periodic report could also result in delisting.
Forward-Looking Statements: The filing contains forward-looking statements regarding the Company's plans to request a hearing and achieve compliance. Actual results may differ materially due to various risks detailed in the Company's Form 10-K.
Key Facts for Investor Verification
- Verify the status of the Company's request for a hearing before the Nasdaq Hearings Panel regarding the $1.00 bid price delisting notice.
- Monitor the Company's stock price to determine if it sustains the $1.00 minimum bid price requirement.
- Review the upcoming Form 10-Q for the period ending September 30, 2020, to confirm continued compliance with the $2,500,000 stockholders' equity requirement.
- Confirm the execution of the sublease agreement and the timeline for the full transition of operations to the new headquarters.